No Data
Agilent Technologies | 10-K: Annual report
Leerink Partners Maintains Agilent Technologies(A.US) With Buy Rating, Raises Target Price to $155
UBS Says 'Underweight the Names With High China Exposure'
Agilent to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Leerink Partners Adjusts Agilent Technologies Price Target to $155 From $150, Maintains Outperform Rating
Whole Genome Sequencing Market Report 2024-2034: Key Player Profiles for Agilent Technologies, BGI Group, Bio-Rad Laboratories, Eurofins Scientific, Illumina, Thermo Fisher Scientific & ProPhase Labs - ResearchAndMarkets.com